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Abstract
Integrase (IN) is an important therapeutic target in the search for anti-Human Immunodeficiency Virus (HIV) inhibitors. This
enzyme is composed of three domains and is hard to crystallize in its full form. First structural results on IN were obtained
on the catalytic core domain (CCD) of the avian Rous and Sarcoma Virus strain Schmidt-Ruppin A (RSV-A) and on the CCD of
HIV-1 IN. A ribonuclease-H like motif was revealed as well as a dimeric interface stabilized by two pairs of a-helices (a1/a5,
a5/a1). These structural features have been validated in other structures of IN CCDs. We have determined the crystal
structure of the Rous-associated virus type-1 (RAV-1) IN CCD to 1.8 A ˚ resolution. RAV-1 IN shows a standard activity for
integration and its CCD differs in sequence from that of RSV-A by a single accessible residue in position 182 (substitution
A182T). Surprisingly, the CCD of RAV-1 IN associates itself with an unexpected dimeric interface characterized by three pairs
of a-helices (a3/a5, a1/a1, a5/a3). A182 is not involved in this novel interface, which results from a rigid body
rearrangement of the protein at its a1, a3, a5 surface. A new basic groove that is suitable for single-stranded nucleic acid
binding is observed at the surface of the dimer. We have subsequently determined the structure of the mutant A182T of
RAV-1 IN CCD and obtained a RSV-A IN CCD-like structure with two pairs of buried a-helices at the interface. Our results
suggest that the CCD of avian INs can dimerize in more than one state. Such flexibility can further explain the
multifunctionality of retroviral INs, which beside integration of dsDNA are implicated in different steps of the retroviral cycle
in presence of viral ssRNA.
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Introduction
During the replicative cycle of retroviruses, the retrotranscribed
viral DNA is integrated into the host chromosome by the viral
integrase protein (IN) [1]. The integration reaction is essential for
theviral life cycle; therefore,INis a keytarget forantiretroviral drug
design [2–5]. Retroviral integration proceeds in three steps, two of
whicharecatalyzedbyIN.First,duringthe39processing,thetwo39
terminal nucleotides of each viral DNA end are removed to
generate CA-39-OH ends with a two-base 59 overhang. Then,
during the strand transfer, the recessed 39-OH viral ends attack the
phosphodiester bonds of the cellular DNA at cleavage sites
separated by four to six base pairs (depending on the virus) and
the viral DNA is joined to the host DNA. Finally, gap filling and
DNA ligation are performed, probably by cellular enzymes [6–8].
Retroviral IN consists of three domains: the zinc-binding N-
terminal domain (NTD), the catalytic core domain (CCD) and the
C-terminal domain (CTD). The IN proteins of the Avian Sarcoma
and Leukemia Viruses (ASLV) and Human Immunodeficiency
Virus (HIV) are approximately 280 amino acids long. The NTD
binds viral DNA [9] and target DNA [10,11] and promotes IN
oligomerization [12]. The NTD is required for 39 processing and
strand transfer in vitro. The central CCD contains an invariant
D,D(35)E motif, which forms a catalytic triad with two sites that
can coordinate various divalent cations (Mg(II), Mn(II), Zn(II),
Cd(II), Ca(II)) [13–16] although Mg(II) is the likely metal cofactor
in vivo. The CCD alone is sufficient to perform an in vitro reaction
termed disintegration, which is the reverse of the strand transfer
reaction [17]. This domain is the most conserved domain across
retroviral INs (.20% sequence identity). It belongs to the
ribonuclease H-like superfamily [18,19] and consists of a five-
stranded mixed b-sheet flanked by a-helices. It has always been
solved as a dimer in partial or entire IN structures from lentivirus
(HIV-1, HIV-2, Simian Immunodeficiency Virus (SIV), Maedi-
Visna Virus (MVV, Bovine Immunodeficiency Virus (BIV)),
alpharetrovirus (Rous Sarcoma Virus (RSV)) and spumavirus
(Prototype Foamy Virus (PFV)) with an intermolecular interface
that always involves two pairs of facing a-helices [20]. The CTD is
known to bind both viral DNA and target DNA [21] and is also
involved in oligomerization [22].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23032The three domains are connected by flexible loops, making the
full-length enzyme difficult to crystallize. Hence, the structure of
IN was first investigated in fragments, such as the two-domains
HIV-1 IN fragment [23,24] and the two-domains RSV IN
fragment [25]. Recently, 3D models of negatively stained full-
length HIV-1 IN, alone or complexed with the cellular cofactor
LEDGF/p75 and either viral or cellular DNA, were proposed by
electron microscopy [26]. The crystal structure of the full-length
IN from PFV complexed with viral [16] and cell DNA [27] was
determined soon thereafter. The EM and crystal structures
confirm that two IN dimers are necessary for concerted
integration. In each dimer, only one CCD active site binds viral
DNA and performs the 39 processing and strand transfer reactions.
The two remaining CCD active sites of the tetramer lie far from
the bound DNA ends and have no apparent role. Taken together,
these structures further suggest that the NTD and the CTD can
move during integration, and their positions diverge with respect
to the CCD.
Rous-associated virus type 1 (RAV-1) is a replication-competent
alpharetrovirus, member of ASLV subgroup A; the INs of this
retrovirus genus are a good model for HIV IN [28]. Herein, we
have determined the crystal structure of the CCD of RAV-1 IN to
1.8 A ˚ resolution. The resulting structure exhibits an unexpected
new dimeric arrangement with potential biological implications.
Our experimental data also explain how crystallization conditions,
as well as the single amino-acid substitution A182T between the
RAV-1 IN CCD and the well-studied RSV-A (strain Schmidt-
Ruppin A) IN CCD [13,14], can favor either dimeric form during
crystal growth. We further show by docking calculations that this
novel dimeric form could accommodate a single-stranded nucleic
acid.
Results
Structure determination and refinement
The CCD of RAV-1 IN, consisting of residues 53–199, was
expressed in Escherichia coli and purified as described in the
‘Materials and Methods’ section. This fragment differs by a single
residue from the CCD of RSV-A IN (A182T substitution), for
which numerous crystal structures have been solved [13,14,29–
31]. Crystallization conditions similar to those published for the
CCD of RSV-A IN that is, citrate buffer at an acidic pH and
HEPES buffer at an alkaline pH [31], were tried but this approach
proved unsuccessful. Hence, a broad screening of conditions was
performed. Crystals were obtained in the presence of Zn(II) and
MES at pH 6.0. They belonged to the hexagonal space group P61
and contained two molecules in the asymmetric unit. Synchrotron
data were collected to 1.8 A ˚ resolution near the Zn-K absorption
edge. The phase problem was solved by molecular replacement
using the monomer of RSV-A IN CCD (PDB entry 1VSD)
structure as the search model. After a few cycles of crystallographic
refinement alternated with manual rebuilding, the final crystal
structure was obtained with an Rfactor value of 19.3% (Rfree
22.8%). The structure contains 271 amino acids in two monomers
termed A and B, 186 water molecules, three Zn(II) ions and one
MES molecule (Figure 1A, left). The N-terminal ends 53–57 of the
two monomers, as well as the loops formed by 145A–152A
(monomer A) and 145B–149B (monomer B) were not observed in
electron density maps and are not included in the model. These
loops are often disordered in retroviral INs [32]. The three
coordinated Zn(II) correspond to the highest peaks in the
calculated anomalous difference Fourier map (29s to 33s).
As a control, the A182T mutant of RAV-1 IN CCD (termed
RAV-1 IN CCDA182T), corresponding to the RSV-A IN CCD
sequence, was purified and the crystallization conditions for both
RAV-1 IN CCD and RSV-A IN CCD were tested; that is, a MES
buffer at pH 6.0 and a citrate buffer at pH 6.2, respectively.
Microcrystals were observed with the first set of conditions, but
were too small to give measurable Bragg peaks. Large crystals were
obtained with the second set of conditions. Further, the huge
crystals of RAV-1 IN CCDA182T were isomorphous to those of
RSV-A IN CCD obtained under the same conditions. They
belonged to space group P43212 with one molecule in the
asymmetric unit. Synchrotron data for these crystals were collected
to 1.55 A ˚ resolutions. The phase problem was solved by a simple
rigid-body refinement followed by restrained refinement using the
structure of RSV-A IN CCD as the starting model. The refined
structure of RAV-1 IN CCDA182T contains 137 residues, 1 citrate
molecule and 122 water molecules (Figure 1A, right). The 145–
152 loop is disordered and is not observed in the electron density
map, as in RSV-A IN CCD.
Overall structure of RAV-1 IN CCD
The 1.8 A ˚ crystal structure of RAV-1 IN CCD consists of two
identical polypeptide chains, termed A and B. The two monomers
can be superimposed with an r.m.s. deviation of 0.4 A ˚ on 132 Ca
pairs after a 180u rotation. The main differences between the two
Ca traces are due to crystal contacts. The differences arise at
residues 174–176, located in a turn between helices a4 and a5
(0.8–1.1 A ˚ between Ca pairs), and at residues 198–199 at the C-
terminal end (3–8 A ˚ between Ca pairs). In the latter case, the short
C-terminal loop following helix a5 folds back toward the protein
core to cap a MES molecule in molecule A (Figure 2A), whereas it
protrudes into the solvent in molecule B. The non-crystallographic
A/B homodimer is compact and approximates a globular ellipsoid
with dimensions of 55640640 A ˚ (Figure 1A). Thus, the tertiary
structure of RAV-1 IN CCD is nearly identical to that of RSV-A
IN CCD, equivalent to that of RAV-1 IN CCDA182T (r.m.s.
deviation of 0.4 A ˚ on 132 Ca pairs) and respects the ribonuclease
H fold (Figure 1A). The A182T substitution, which also occurs
between the Schmidt-Ruppin strains B and A of RSV IN, does not
affect the tertiary structure of avian INs.
The active site of RAV-1 IN CCD
The invariant acidic residues of the catalytic triad (Asp64,
Asp121 and Glu157 in RAV-1 IN) were accurately orientated in
the electron density map. They form a pocket at the surface of the
RAV-1 IN CCD monomer, which is located 15 A ˚ away from the
A/B dimeric interface. The carboxylate group of Asp64 is situated
at the centre of the triad and interacts with Asp121 through a
Zn(II) ion from the crystallization solution. This ion occupies the
divalent cation-binding site termed site I in retroviral INs. It also
coordinates two water molecules and the imidazole group of
His198, which belongs to a symmetry-related molecule (Figure 2B).
Such a penta-coordinated metal ion has never been observed in
the active site of INs before. The side chain of Glu157 points freely
towards the solvent, as observed in the structure of RSV-A IN
CCD in complex with one Mg(II) coordinated at site I (PDB entry
1VSD). This residue rotates when accommodating the second
catalytic Zn(II) in site II [14]. The present active site of RAV-1 IN
with its coordinated histidine is very similar to that of influenza
virus polymerase, which was solved recently [33]. In this structure,
acidic and basic catalytic residues coordinate two divalent cations,
which are very likely to be responsible for the endonuclease
activity of the whole protein. No biological interpretation could be
deduced from this structural resemblance though. A further
structural comparison was performed, with the active site of full-
length PFV IN in complex with Mg(II) and raltegravir, an
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3L2T). It appeared that the coordinated side chain of the
symmetry-related His198 occupies the position of two chelating
oxygen atoms linked to the pyrimidine group of the IN inhibitor.
The same observation was made in a comparison with PFV IN
complexed with Mg(II) and elvitegravir, another antiretroviral
molecule (PDB entry 3L2U). Again, the IN inhibitors occupy the
position devoted to His198 that mimics the coordinated nucleotide
in the crystal structure of RAV-1 IN CCD.
A new dimeric assembly
The canonical dimeric interface of RSV-A IN CCD (equivalent
to RAV-1 IN CCDA182T) which generally involves two pairs of
facing a-helices of each monomer (pairs a1/a5; Figure 1A, right), is
not visible in the crystal packing of RAV-1 IN CCD. The present
A/Bdimer buries three pairs of facinghelices (a3A/a5B, a1A/a1B,
a3B/a5A; Figure 1A, left) in a new intermolecular interface, which
canbeobtained fromthecrystallographicdimerofRSV-AINCCD
by a 15 A ˚ translation of one monomer along the other. Thus, helix
a5 faces helix a1 of the complementary monomer in RSV-A IN
CCD, and helix a3 of the complementary monomer in RAV-1 IN
CCD. Moreover, helices a1 of monomers A and B now run almost
parallel to the non-crystallographic two-fold axis and are locked
together via a buried Zn(II) that coordinates the imidazole rings of
His103A and His103B (Figure 1A, left). This central Zn(II) also
coordinates two water molecules in a perfectly tetrahedral
coordination sphere. The area of the buried surface at the new
CCD/CCD interface, 740 A ˚ 2 per monomer, is similar to that
previously observed in RSV-A IN; that is, 750 A ˚ 2 per monomer.
The distance between the active sites of the two CCDs is preserved
(35 A ˚), as is the distance between the two CCD N-termini (25 A ˚),
while the distance between the two CCD C-termini increases
significantly (from 20 A ˚ to 35 A ˚). The web server PISA [34]
suggests that the new dimeric assembly is stable in solution. The
novel interface buries an equal number of polar and non-polar
residues (Table S1) and more than 50% of contacting residues are
preserved between RAV-1 IN CCD and RSV-A IN CCD
(Figure 1B). For example, the ion pair between His103 (helix a1)
and Glu187 (helix a5) of the complementary monomer that was
highlighted in RSV-A IN CCD [35] is substituted by an equivalent
intermolecular contact between Arg137 (helix a3) and the same
Glu187 (helix a5) in RAV-1 IN CCD.
Figure 1. Primary, secondary and tertiary structure representations of RAV-1 IN CCD and RAV-1 IN CCDA182T homodimers. (A)
Ribbon representation of RAV-1 IN CCD (left) and RAV-1 IN CCDA182T (right) with monomer A in blue and monomer B in yellow. The three catalytic
residues (D64, D121 and E157) are represented by red sticks, H103 by green sticks and residue 182 (Ala in RAV-1WT, Thr in RAV-1A182T) by cyan sticks.
The MES molecule located at the interface of RAV-1 is shown in orange, while zinc ions are represented by dark spheres. Citrate molecules are colored
purple in RAV-1A182T.( B) Multiple sequence alignment of RAV-1, HIV-1 and PFV IN CCDs. Secondary structure elements are indicated above the
alignment. Identical and conserved residues according to physicochemical criteria are highlighted in red and yellow boxes, respectively. Pink and
green triangles indicate residues involved in the dimeric interfaces of RAV-1 IN CCD (novel) and RAV-1 IN CCDA182T (canonical), respectively. Red stars
indicate the three invariant catalytic residues, while residue A182 of RAV-1 is highlighted in cyan. Figures 1A and 1B were generated with PyMOL [60]
and ESPript [61], respectively.
doi:10.1371/journal.pone.0023032.g001
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in any dimeric interface (canonical or novel). This residue is
located on the outer edge of helix a5, a portion of which is
accessible to solvent in both the RSV-A IN CCD and RAV-1 IN
CCD crystals (Figure 1A). The A182T substitution mostly affects
the side-chain orientation of the neighboring Arg179 of the a4-a5
loop. This arginine is hydrogen bonded to the side-chain oxygen
atom OG of Thr182 in RSV-A IN CCD (Figure 2D), whereas a
similar contact is impossible with the aliphatic Ala182 in RAV-1
IN CCD. There, the side chain of the arginine has rotated by 130u
around its CG-CD bond to mediate a crystal contact with the side-
chain carboxylate in the Asp173 of a neighboring monomer
(Figure 2C). Thus, the A182T substitution influences crystal
assembly via Arg179 and, either large tetragonal crystals or tiny
hexagonal microcrystals are observed for RAV-1 IN CCDA182T,
whereas only hexagonal crystals are obtained for RAV-1 IN CCD.
A buried MES molecule
The novel dimeric interface buries a MES in a canal located
between helix a5 of molecule A and helix a3 of molecule B
(Figure 1A, left). The O1 oxygen atom of the morpholino group is
oriented toward the bulk solvent, while the sulfonate group
penetrates deeply into the interface. The morpholino group is
further cradled by hydrophobic interactions with Tyr194A,
Phe199A and Trp138B (Figure 2A). Its N4 nitrogen atom
establishes a direct hydrogen bond with the hydroxyl group of
Tyr194A, while the adjacent sulfonate group is stabilized by the
guanidinium group of Arg137B. In comparison, a bound HEPES
molecule is observed in the alkaline structure of RSV-A IN CCD,
whereas a bound citrate is observed in the acidic structure of the
same fragment [31] and in the equivalent RAV-1 IN CCDA182T.
However, neither of these two buffer molecules is involved in the
canonical interface of RSV-A IN CCD. The HEPES molecule,
which resembles MES in its sulfonate group and a six-atom cycle,
is lodged at the CCD surface along the tips of loops b1b2 and
b3a1, while the citrate molecule caps the N-terminal extremity of
helix a5 (Figure 1A, right).
The H103C mutant
In order to give proof that the novel assembly is not a
crystallization artifact, a mutant able to stabilize the new dimeric
interface in solution was designed. Molecular modeling shows that
Figure 2. MES binding site and important crystallographic contacts in RAV-1 IN CCD and RAV-1 IN CCDA182T. (A) The MES binding site
at the novel dimeric interface of RAV-1 IN CCD. (B) A close view of the active site of RAV-1 IN CCD. The zinc ion in site I is represented by a yellow
sphere. This ion is penta-coordinated by D64 and D121 (blue), H198 from a symmetry-related monomer (green) and two water molecules (red
spheres). (C) A close view of RAV-1 IN CCD, focused on residue R179 near A182. Monomers are colored in light blue and pale orange (symmetry-
related molecule). (D) The counterpart region for RAV-1 IN CCDA182T. The A182T mutation promotes a reorientation of R179 side-chain.
doi:10.1371/journal.pone.0023032.g002
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formation of a disulfide bond at the new interface and covalently
lock the novel quaternary structure. Thus, RAV-1 IN CCDH103C
was produced in specific bacteria (see ‘Materials and Methods’)
and purified without b-mercaptoethanol. RAV-1 IN CCDH103C
was analyzed on a denaturing SDS-PAGE gel with and without
reducing agent and revealed by silver staining. RAV-1 IN
CCDH103C migrated as a dimer in non-reducing conditions and
as a monomer in reducing conditions (Figure S1). Mass
spectrometry analyses were performed on reduced and non-
reduced digested peptides to confirm the presence of the disulfide
bond between Cys103 of monomers A and B and the formation of
the novel assembly in solution.
A novel median basic groove
As described previously by Bujacz et al., the canonical dimeric
interface of RSV-A IN CCD contains a central cavity bordered by
hydrophilic residues [35]. This cavity is conserved in HIV IN and
has been investigated as a target for allosteric inhibitors [36]. A
projection of molecular electrostatic potentials shows that this
central invagination becomes a highly basic groove in RAV-1 IN
CCD and strips the middle of the protein surface at the dimeric
interface away from the catalytic sites (Figure 3A). Inspection of
the narrow groove basement reveals three small pockets arranged
at regular intervals so as to accommodate a linear single-stranded
nucleic acid. The two outer pockets are also the gates of two
symmetry-related canals running along the intermolecular inter-
face perpendicularly to the medium groove (Figure 3). The
distance between the central and outer pockets is 10 A ˚. Residues
His103A and His103B which are bridged by the central Zn(II)
constitute the bottom of the middle pocket.
A ‘‘blind docking’’ experiment was performed with a single-
stranded RNA aptamer against the entire surface of our RAV-1
IN CCD dimer. All of the highest score solutions correspond to
RNA fragments bound at the level of the median basic groove.
According to these predictions, heterocycles of purine and
pyrimidine bases could fit in the three bottom pockets of the
groove with the phosphodiester chain of the RNA exposed to the
solvent. The central pocket can alternatively bind to a phosphate
group of the RNA backbone. In this case, the backbone adopts a
linear twisted conformation, made possible by the high degree of
flexibility of the chain.
Discussion
RAV-1 IN displays standard activities for 39 processing, strand
transfer reactions and concerted DNA integration in vitro [28,37–
39]. The CCD:CCD interface of IN with two pairs of facing a-
helices (a5/a1, a1/a5) has been the only form observed until now.
It displays a significant interaction area, the values of which range
from 1500–1300 A ˚ 2 for HIV-1 and SIV to 750–700 A ˚ 2 for RSV
and PFV. A crystal form termed II of the CCD of BIV IN was
found of particular interest, because it was observed that a dimer
of canonical dimers (interaction area 1250 A ˚ 2) was stabilized by a
short interface named face-to-face (interaction area 580 A ˚ 2), which
could also occur during the formation of the IN-DNA complex
[40]. Such face-to-face interface between canonical dimers is not
observed in the structure of the PFV intasome [16]. Lower to
negligible interface interactions are observed for other domains
(NTD or CTD) of INs [20]. Obtaining a novel dimeric
arrangement for the CCD of RAV-1 IN that differs from all
structures of INs published to date was a real surprise. Our first
assumption was that our novel dimeric arrangement with its three
pairs of facing a-helices at the interface (a3/a5, a1/a1 and a5/a3)
was a crystallization artifact, but the formation of a covalently
bonded dimer for the H103C mutant gave insight on the new
dimeric assembly during bacterial production. Furthermore, the
amount of buried surface in the new CCD:CCD interface is
similar, ,750 A ˚ 2, to that observed in the canonical interface of
RSV-A IN, and the solvation free energy gain calculated with
PISA is in agreement with the formation of a biological
interaction. Zn(II) still plays an important role in the formation
of the CCD-CCD interface by locking two facing histidines and
may favor on its own the formation of a non-biological dimer.
Figure 3. The novel dimer in complex with a 4-base RNA
fragment, as predicted by docking experiments. (A)T h e
molecular surface of the RAV-1 IN CCD dimer with the five top scored
docking solutions (in stick representation) bound at the level of the
median basic groove. Surfaces are colored according to electrostatic
potential (red negative charges; blue positive charges). The three
binding pockets are boxed in yellow while locations of the two active
sites are indicated by black asterisk. (B) A cross-section of the molecular
surface of the RAV-1 IN CCD dimer along the main axis of the basic
groove demonstrating the five top scored docking conformations.
Cavities and canals are colored light grey while the three binding
pockets are indicated by green circles. The MES molecule buried at one
canal exit is circled in yellow. The electrostatic potential map and the
molecular surfaces were calculated with GRASP [62].
doi:10.1371/journal.pone.0023032.g003
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cofactor to stabilize an alternate conformation of the CCD as is
discussed in the following paragraphs. Avian INs are highly
conserved in sequence and the dimeric association of either of the
two forms can probably be achieved in most cases. As an
illustration, our crystallization studies show that the two crystal
forms (tetragonal and hexagonal corresponding to the canonical
and novel interface, respectively) can be obtained for the RAV-1
IN CCDA182T single mutant, whose sequence is identical to that of
the RSV-A IN CCD peptide. Another interesting aspect of our
results is to establish that the single mutation A182T, which is
located away from the dimerization interface, has a considerable
impact on the CCD assembly although the tertiary structure of the
fragment is preserved. Most crystallographic studies of INs,
especially of HIV-1 IN, were only possible after the introduction
of mutations in the CCD to yield soluble proteins. In consequence,
we conducted further analyses to better identify the molecular
determinants of our novel interface.
The role of the pH and of the buffer
Previous studies on different types of entire INs including RAV-
1 IN demonstrate that the protein exists in a monomer-dimer or a
monomer-dimer-tetramer equilibrium [28,38,41]. However, our
size exclusion chromatography (SEC) elution profiles of RAV-1 IN
CCD and RAV-1 IN CCDA182T monitored during protein
purification are consistent with a monomeric protein. These
results were confirmed by SEC-MALS with a concentration as
high as 2.3 mg/ml (140 mM) at sample injection (Figure S2).
Consequently, we assume that the dimeric association of either of
the two forms occurs during crystallization and depends on the
crystallization solution.
We have tested the influence of pH on the crystal assembly of
RAV-1 IN CCD, by using a wide range of pH levels from 6 to 10
in the presence of 10 mM of ZnCl2. Crystals were obtained only at
the mild acidic pH of 6 with a MES buffer. The canonical dimeric
form of RSV-A IN CCD can be obtained in a citrate buffer at a
similar pH [31]. Thus, an acidic solution is not the determinant of
the novel quaternary structure.
The role of Zn(II)
The new interface is obtained in presence of Zn(II), which is an
essential cofactor for IN because it is implicated in the folding of
the NTD [12,42] . It can also be coordinated as a cofactor in two
sites of the active site termed I and II [29]. Zn(II) has also been
shown to stimulate the dimerization of HIV IN in association with
Mg(II) [43]. Zinc binding has been studied intensively for the
canonical RSV-A IN CCD [14,29]. Crystal-soaking experiments
were performed in solutions containing 2 mM to 100 mM ZnCl2,
and four coordinated Zn(II) were subsequently observed at sites I
and II of the catalytic pocket and at two distant sites termed III
and IV. Interestingly, binding site similarities are observed
between this soaked structure and the novel crystal structure of
RAV-1 IN CCD. Site I is conserved in both forms, with a Zn(II)
bridging the catalytic residues Asp64 and Asp121. This further
demonstrates that the novel dimeric assembly has no influence on
the topology of the active site. Accordingly, site II is not occupied
as in most retroviral INs. Structural similarities between sites III
and IV raise more questions, because the local environments of the
two dimeric forms are distinct. In canonical RSV-A IN CCD, the
two remaining Zn(II) are found at the surface of the protein and
are coordinated by His103 (site III) and His198 (site IV),
respectively. In the novel RAV-1 IN CCD structure, His103 is
buried deep in the dimeric interface and is connected to His103 of
the complementary monomer via one Zn(II) ion (Figure 1A).
His198 is still located at the protein surface, but it is coordinated to
site I of a symmetry-related monomer via a second Zn(II)
(Figure 2B). Thus, sites I and IV of RSV-A IN CCD merge into
a single penta-coordinated site I in RAV-1 IN CCD, while sites III
of each RSV-A IN monomer fuse into a central Zn(II) site to lock
the RAV IN dimer together.
From these data, it appears that Zn(II) plays an important role
in the formation of the novel interface as it does for the folding of
the NTD. In our case, this divalent cation binds to the accessible
His103 and His198 of the monomeric fragment and promotes
dimerization and crystal growth. As an illustration, we produced
and tried to crystallize the H103A mutant and the H103A/A182T
double mutant of RAV-1 IN CCD using the ‘‘new’’ and the
‘‘canonical’’ crystallization conditions. No crystal was obtained
with RAV-1 IN CCDH103A, and large crystals of RAV-1 IN
CCDH103A/A182T were observed but with the ‘‘canonical’’
condition only. These results, like those obtained with the the
H103C mutant, suggest that both His103 and a bound Zn(II) are
necessary to the creation of the new interface.
We also tried to characterize the emergence of the novel
quaternary assembly in solution by Dynamic Light Scattering
(DLS) and Small Angle X-ray Scattering (SAXS). However, the
CCD domain of RAV-1 IN tends to aggregate in the presence of
zinc so no reliable measures were obtained.
The putative biological role of the novel interface
The biological relevance of the novel dimeric form should now
be questioned with respect to the retroviral cycle. Although the Ca
trace of each CCD monomer is preserved, the novel association
might result in significant displacements of the two terminal
domains fused to the CCD, affecting the entire protein. However,
in vitro strand transfer reactions within the entire RAV-1 IN
protein are optimal at alkaline pH in the absence of zinc [37].
These experimental conditions are the opposite of those required
for the formation of the novel interface in cristallo, and we believe
that a biological function should be investigated apart from the
integration mechanism. IN exhibits karyophilic properties and one
can also propose that the basic groove located at the novel
interface could be used as a karyophilic determinant. This motif
could complement the nuclear localization signal (NLS) that was
identified in the region linking the CCD and the CTD of RSV IN
[44,45].
IN is also involved in reverse transcription and virus assembly,
as shown for HIV-1 [46–48]. These two steps of the viral cycle
occur in presence of viral RNA, and the potential ability of the
new basic groove to bind a single-stranded nucleic acid chain has
enabled us to suggest possible biological roles for the novel
interface. ASLV reverse transcriptase (RT) is an ab heterodimer,
which contains the polymerase, RNase H, and IN domains within
the 95 kDa b subunit. Cleavage of the IN domain from the b
subunit produces the 63 kDa a subunit and free IN enzyme. One
function of the IN domain in the b subunit is to increase the
affinity of RT to its substrate [49,50]. Therefore, we speculate that
this new quaternary structure may contribute to the binding of
viral RNA or the single-stranded strong stop DNA generated
during reverse transcription.
Finally, this dimeric structure shows that the binding of a MES
morpholino group within the new interface has induced an
important movement of residue F199 at the C-terminus of helix
a5. This residue is spatially equivalent to F185 in HIV IN, which is
often mutated to lysine or histidine in crystallographic studies in
order to increase protein solubility [23,51]. Such a substitution
may impair MES fixation and could have hindered the detection
of the novel dimeric interface in HIV IN.
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least two intermolecular interfaces permitting multifunctionality. A
parallel could be drawn with other retroviral proteins, such as Vif
in lentivirus, which contain intrinsically disordered regions and
can therefore interact with multiple partners [52]. Retroviruses
with limited genome length could use this strategy to generate
proteins with flexible structures to mediate more than one step of
the viral cycle.
Materials and Methods
Cloning the RAV-1 IN CCD sequence: pETG10a-
INRAV1CCD
The DNA sequence encoding the IN catalytic core domain of
RAV-1 (residues 53–199) was amplified by PCR from the
pET30a-INRAV1 plasmid [37]. The sequence has been deposited
in GenBank nucleotide database under accession number
JF514545. The fragment was cloned using Gateway Technology
(Invitrogen); the 59 attB PCR primer was designed with a thrombin
cleavage site. pDONR223 was used as donor vector to generate an
entry clone. pETG10a, containing a hexahistidine tag, was used as
the expression vector. The constructed expression vector was
confirmed by DNA sequencing.
Site-directed mutagenesis
The pETG10a-INRAV1CCDA182T, pETG10a-INRAV1CCD-
H103A, pETG10a-INRAV1CCDH103A/A182T, pETG10a-IN-
RAV1CCDH103C and pET30a-INRAV1-H130C sequences were
created by site-directed mutagenesis (Stratagene QuickChange kit)
using pETG10a-INRAV1CCD and pET30a-INRAV1 as a tem-
plate for the following mutagenic primers (mutations are shown as
lowercase letters): 59-GTTCCCCCTGTTTGCTggtGGGGATT-
CTTTTCATAAAG-39 (F-A182T), 59-CTTTATGAAAAGAA-
TCCCCaccAGCAAACAGGGGGAAC-39 (R-A182T); 59-GC-
CGTGGCCCAATGagcTTGTGCAGCAACCG-39 (F-H103A),
59-CGGTTGCTGCACAAgctCATTGGGCCACGGC-39 (R-H-
103A) and 59- GCCGTGGCCCAATGacaTTGTGCAGCAA-
CCG-39 (F-H103C), 59- CGGTTGCTGCACAAtgtCATTGG-
GCCACGGC-39 (R-H103C). Mutations to the expression vector
were confirmed by DNA sequencing. pETG10a-INRAV1CCD,
pETG10a-INRAV1CCDA182T, pETG10a-INRAV1CCDH103A
and pETG10a-INRAV1CCDH103A/A182T were introduced into
E. coli BL21 (DE3) pLysS competent cells (Novagen) for protein
expression. pETG10a-INRAV1CCDH103C was introduced in E.
coli Rosetta-gami
TM B(DE3)pLysS competent cells (Novagen) for
protein expression and formation of target protein disulphide bond
in the bacterial cytoplasm.
Expression and purification of RAV-1 IN CCD and RAV-1
IN CCD mutants (A182T, H103A, H103A/182T)
An overnight culture (5 ml) from a single colony containing the
desired plasmid was used to inoculate 1 l fresh LB medium in the
presence of ampicillin (50 mg/ml). The culture was incubated at
37uC, and shaken at 220 rpm until an A600=0.8,0.9 was
reached. Overexpression of the proteins was induced by 1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG) overnight at 25uC.
Then, bacteria were harvested by centrifugation at 30006 g for
10 min and stored at 280uC. For purification, the thawed
bacterial pellet was sonicated in 20 ml of buffer A (0.5 M NaCl,
10 mM imidazole, 5 mM b-mercaptoethanol, 20 mM Tris-HCl,
pH 8.0) in the presence of 100 ml Halt Protease Inhibitor Cocktail
(Pierce) and DNAse/RNAse (final concentration 50 mg/ml). The
lysate was cleared by centrifugation (45 min, 10,000 rpm at 4uC)
and then filtered through a 0.45 mm filter. The supernatant
containing soluble His-tagged proteins was loaded on an Ni
2+
charged 1 ml HiTrap Chelating HP column (GE Healthcare)
using the A ¨KTA chromatography system. The column was
extensively washed with buffer B (0.5 M NaCl, 20 mM imidazole,
5m Mb-mercaptoethanol, 20 mM Tris-HCl, pH 8.0) and with
5 ml Buffer B2 (1 M NaCl, 20 mM imidazole, 5 mM b-
mercaptoethanol, 20 mM Tris-HCl, pH 8.0). IN proteins were
eluted with 0.5 M NaCl, 500 mM imidazole, 5 mM b-mercapto-
ethanol, 20 mM Tris-HCl, pH 8.0 using a linear gradient. Eluted
fractions were collected and analysed by SDS-PAGE. The
hexahistidine tag was removed by overnight digestion with
thrombin protease (Amersham Biosciences) at 4uC. Digested
protein solutions were loaded on a Ni
2+ charged 1 ml HiTrap
Chelating HP column (GE Healthcare); undigested proteins and
free tags were fixed on the column while digested protein was
recovered in the flow through. The purity of the recovered protein
was analyzed by SDS-PAGE and silver staining. Protein
concentration was determined according to a Bradford assay
(Bio-Rad Laboratories) using BSA as standard and then
concentrated to 10 mg/ml using a 10 kDa molecular-weight cut-
off membrane (Vivascience).
Crystallization of RAV-1 IN CCD and ‘‘canonical’’ RAV-1 IN
CCDA182T
Crystallization conditions were searched for RAV-1 IN CCD
using the sitting-drop vapour-diffusion method and commercial
kits from Hampton Research, Molecular Dimensions Limited
(MDL) and Qiagen. Droplets composed of 0.3 ml protein solution
at 10 mg/ml and an equal volume of crystallization solution were
equilibrated against 100 ml reservoir solution within a sealed well
at 18uC. A crystal was observed for condition 24 of MDL PACT
premier (10 mM ZnCl2, 20% (w/v) PEG 6000, 100 mM MES,
pH 6.0). Crystals reached maximum dimensions of 2062065 mm
3
within a week. Their size was improved to 1506150680 mm
3 with
a macroseeding technique using drops containing a 2 ml protein
solution and a 2 ml precipitant solution. Crystals were mounted in
a nylon loop and cryoprotected by adding 0.4 ml ethylene glycol to
the hanging drop before flash-freezing in liquid nitrogen. Crystals
of RAV-1 IN CCDA182T were obtained in hanging drops at 18uC
by mixing 1 ml protein solution (5 mg/ml) and 1 ml reservoir
solution with either the crystallization condition of the wild-type or
a crystallization condition for RSV-A IN CCD (20% (w/v) PEG
4000, 10% isopropanol and 0.1 M Na citrate pH 6.2). Micro-
crystals were obtained under the first set of conditions.arge crystals
with maximum dimensions of 20061506150 mm
3 were obtained
under the second set of conditions.
Data collection and structure determination
A synchrotron data set for RAV-1 IN CCD was collected to
1.8 A ˚ resolution from a crystal cooled to 100 K at ESRF beamline
ID29 (Grenoble, France) at a wavelength of 1.28 A ˚. Data were
processed with XDS/XSCALE [53]. The phase problem was
solved by molecular replacement using the program AMoRe [54].
The final crystal structure, with two polypeptide chains named A
and B, was obtained by alternating cycles of restrained refinement
in Refmac5 [55] and manual rebuilding in Coot [56].
WHATCHECK [57] was used to assess the geometric quality of
the model (94.2% of the residues in the most favored region of the
Ramachandran plot). A second synchrotron data set was collected
to 1.55 A ˚ resolution at the ESRF beamline BM30A at a
wavelength of 0.98 A ˚, under cryo-conditions (100 K), from a
crystal of RAV-1 IN CCDA182T. The phase problem was solved by
rigid-body refinement with Refmac5 prior to restrained refine-
ment. Additional data collection and refinement statistics are
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structure factors of crystal structures described herein have been
deposited in the RCSB Protein DataBank (http://www.rcsb.org)
under the accession codes 3O4N (RAV-1 IN CCD) and 3O4Q
(RAV-1 IN CCDA182T mutant).
Docking experiments
A single-stranded RNA molecule comprising four bases was
designed. The number of bases employed was determined by a
computational limit to the number of rotatable bonds allowed.
The 1.1 A ˚ atomic resolution crystal structure of the DNA
octanucleotide d(pATTCATTC) was used as the template (PDB
entry 284D). We truncated and modified this structure to obtain
our final RNA fragment, pCAUUp. This ligand and the receptor
structure of RAV-1 IN CCD were then prepared with Auto-
DockTools [58]. A ‘‘blind docking’’ was subsequently carried out
on the entire surface of the dimer with the program AutoDock
Vina [59]. Once a binding area was identified, new docking cycles
were achieved with a reduced search space encompassing the site
of interest. Flexible-ligand docking with grid-based energy scoring
was conducted with the program’s standard protocol [59].
Supporting Information
Figure S1 Visualization of disulfide bonds in RAV-1 IN
CCDH103C by SDS-PAGE in non-reducing and reducing
conditions. RAV-1 IN CCDH103C was produced in E. coli
Rosetta-gami
TM B(DE3)pLysS competent cells (Novagen) as
described in ‘Materials and Methods’. Track 1: RAV-1 IN in
reducing conditions (b-mercaptoethanol 5%). A single band
corresponding to the monomeric form is observed (theoretical
molecular weight of 16.3 kDa). Track 2: RAV-1 IN CCDH103C in
non-reducing conditions. Monomeric and dimeric forms are
observed (theoretical MW of 16.3 kDa and 32.6 kDa, respective-
ly). The apparition of the high molecular weight strip attests the
production of dimeric RAV-1 IN CCDH103C with disulfide bonds.
Track 3: molecular weight markers. RAV-1 IN CCDH103C was
loaded onto a 12% SDS PAGE in reducing and non-reducing
conditions, and the protein bands were detected by Coomassie
Blue Staining. The two bands corresponding to RAV-1 IN
CCDH103C with or without a putative intramolecular disulfide
bond were excised and cut to perform in gel trypsin digestion
without reduction and alkylation [63]. The tryptic peptides were
analysed by MALDI-TOF and mass spectra were recorded on a
Voyager DE-PRO (AB Sciex).
(TIF)
Figure S2 SEC-MALS/RI analysis of RAV-1 IN CCD in
solution. Determination of the oligomerization state of RAV-1
IN CCD in solution was studied by the combination of UV
spectrometry, multi-angle static light scattering (MALS), and
refractometry, coupled on-line with an analytical size exclusion
chromatography (SEC) column. UV, MALS and refractometry
measurements were achieved with a Photo Diode Array 2996
Table 1. Data collection and refinement statistics.
RAV-1 IN CCD ‘‘Canonical’’ RAV-1 IN CCDA182T
Data collection
Space group P61 P43212
Cell dimensions:
a, b, c (A ˚) 107.5, 107.5, 50.9 65.5, 65.5, 79.2
a, b, c (u) 90, 90, 120 90, 90, 90
Vm (A ˚3.Da
21) 2.6 2.8
Solvent content (%) 52 55
Resolution range (A ˚) 19.7–1.8 (1.95–1.8) 20.0–1.55 (1.60–1.55)
Total number of reflections 162065 (33802) 111679 (7650)
Number of unique reflections 30860 (6613) 24970 (2171)
Rsym (%) 7.6 (39.9) 4.9 (25.6)
I/s(I) 11.6 (3.4) 20.9 (5.4)
Completeness (%) 99.0 (99.0) 97.4 (95.3)
Redundancy 5.3 (5.1) 4.5 (3.5)
Refinement
Resolution (A ˚) 1.8 1.55
Rfactor/Rfree (%) 19.3/22.8 16.4/21.1
No. atoms:
protein (non-hydrogen) 2099 1079
ligand/ion 15 13
Water 186 122
Overall B-factor (A ˚2) 31.7 15.2
R.m.s. deviations:
bond lengths (A ˚) 0.020 0.026
bond angles (u) 2.34 1.72
Values in parentheses are for highest-resolution shell.
doi:10.1371/journal.pone.0023032.t001
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rEX (Wyatt Technology), respectively. Size exclusion chromatog-
raphy was carried out on an Alliance 2695 HPLC system (Waters)
using a KW803 column (Shodex) run in a buffer containing
20 mM Tris-HCl, 500 mM NaCl and 5 mM b-Mercaptoethanol
at pH 7.5 with a flow rate of 0.5 ml/min. The molar mass (left
axis, bold line) and the UV280 nm absorbance (right axis, regular
line) are plotted as a function of the column elution volume. SEC-
MALS/RI/UV characterization revealed a mass of 198006
210 g/mol and 176906190 g/mol, respectively. These data attest
the monomeric nature of the protein.
(TIF)
Table S1 Residues involved in the novel dimeric interface.
(DOC)
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